IDRA Share Price

Open 1.72 Change Price %
High 1.72 1 Day -0.05 -3.11
Low 1.53 1 Week 0.00 0.00
Close 1.56 1 Month -1.11 -41.57
Volume 5405940 1 Year -0.32 -17.02
52 Week High 2.87
52 Week Low 1.30
IDRA Important Levels
Resistance 2 1.74
Resistance 1 1.66
Pivot 1.60
Support 1 1.46
Support 2 1.38
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

IDRA Technical Analysis 5
As on 31st Oct 2017 IDRA Share Price closed @ 1.56 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.89 & Strong Sell for SHORT-TERM with Stoploss of 2.10 we also expect STOCK to react on Following IMPORTANT LEVELS.
IDRA Target for December
1st Target up-side 2.4
2nd Target up-side 3
3rd Target up-side 3.59
1st Target down-side 0.72
2nd Target down-side 0.12
3rd Target down-side -0.47
IDRA Other Details
Segment EQ
Market Capital 20456252.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.iderapharma.com
IDRA Address
IDRA
167 Sidney Street
Cambridge, MA 02139
United States
Phone: 617-679-5500
Fax: 617-679-5592
IDRA Latest News
Interactive Technical Analysis Chart Idera Pharmaceuticals, Inc. ( IDRA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Idera Pharmaceuticals, Inc.
IDRA Business Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer�s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.